FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 ...

For decades, osteoporosis has meant a slow, one way slide toward fragile bones and fracture risk, managed but rarely truly ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

UPF scientists have discovered this 7% of critical areas based on their pioneering analysis model that allows minimizing the ...

One major warning sign of osteoporosis is a “fragility fracture”—a broken bone caused by something minor like a simple fall.

Although there are several effective anti-osteoporosis drugs on the market today, new therapies with improved safety profiles and efficacy are still needed. The FDA called osteoporosis-related ...

Boston-based Beth Israel Deaconess Medical Center played a role in a new FDA decision that allows bone mineral density, measured through noninvasive imaging, to serve as a qualified endpoint in ...

But new research suggests that a simple blood test may be able to predict osteoporosis risk, allowing doctors to intervene ...

The Foundation for the National Institutes of Health (FNIH) announces that the Food and Drug Administration (FDA) has qualified the treatment-related change in hip bone mineral density (BMD) as a ...

Adding romosozumab to ongoing denosumab treatment shows increased lumbar spine bone mineral density with preserved anabolic ...